MYCN Function in Neuroblastoma Development

Dysregulated expression of the transcription factor MYCN is frequently detected in nervous system tumors such as childhood neuroblastoma. Here, gene amplification of is a single oncogenic driver inducing neoplastic transformation in neural crest-derived cells. This abnormal expression is one of the...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2021-01, Vol.10, p.624079-624079
Main Authors: Otte, Jörg, Dyberg, Cecilia, Pepich, Adena, Johnsen, John Inge
Format: Article
Language:English
Subjects:
cancer stem cell
childhood cancer
MYCN
neural crest
neuroblastoma
Oncology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c566t-4b35dd7b6d248267fc77b9d6e42fa7e2b273f172f0c93bf188025c4900f0ede73
cites cdi_FETCH-LOGICAL-c566t-4b35dd7b6d248267fc77b9d6e42fa7e2b273f172f0c93bf188025c4900f0ede73
container_end_page 624079
container_issue
container_start_page 624079
container_title Frontiers in oncology
container_volume 10
creator Otte, Jörg
Dyberg, Cecilia
Pepich, Adena
Johnsen, John Inge
description Dysregulated expression of the transcription factor MYCN is frequently detected in nervous system tumors such as childhood neuroblastoma. Here, gene amplification of is a single oncogenic driver inducing neoplastic transformation in neural crest-derived cells. This abnormal expression is one of the strongest predictors of poor prognosis. It is present at diagnosis and is never acquired during later tumorigenesis of non-amplified neuroblastoma. This suggests that increased expression is an early event in these cancers leading to a peculiar dysregulation of cells that results in embryonal or cancer stem-like qualities, such as increased self-renewal, apoptotic resistance, and metabolic flexibility.
doi_str_mv 10.3389/fonc.2020.624079
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_aaad09d4a800423f841c6eaad15e9530</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_aaad09d4a800423f841c6eaad15e9530</doaj_id><sourcerecordid>2489599632</sourcerecordid><originalsourceid>FETCH-LOGICAL-c566t-4b35dd7b6d248267fc77b9d6e42fa7e2b273f172f0c93bf188025c4900f0ede73</originalsourceid><addsrcrecordid>eNpVkc1v1DAQxS0EolXbOye0R4SUZeLP-IKEFgqV2nJpJThZjj0uKUm82EkR_z1eslRdXzx68-bnj0fIqxrWjDX6XYijW1OgsJaUg9LPyDGljFeas2_Pn9RH5CzneyhLCqiBvSRHjIlGUFEfk7dX3zfXq_N5dFMXx1U3rq5xTrHtbZ7iYFcf8QH7uB1wnE7Ji2D7jGf7_YTcnn-62XypLr9-vth8uKyckHKqeMuE96qVnvKGShWcUq32EjkNViFtqWKhVjSA06wNddMAFY5rgADoUbETcrFwfbT3Zpu6waY_JtrO_BNiujM2TZ3r0VhrPWjPbQPAKQsNr53EItYCtWBQWNXCyr9xO7cHtL30s1RouOSs3vnfL_7SGdC78uxk-4Oxw87Y_TB38cGoRjHFRAG82QNS_DVjnszQZYd9b0eMczblT7TQWjJarLBYXYo5JwyPx9RgdgmbXcJml7BZEi4jr59e73Hgf57sL-epoiw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2489599632</pqid></control><display><type>article</type><title>MYCN Function in Neuroblastoma Development</title><source>PubMed Central (Open Access)</source><creator>Otte, Jörg ; Dyberg, Cecilia ; Pepich, Adena ; Johnsen, John Inge</creator><creatorcontrib>Otte, Jörg ; Dyberg, Cecilia ; Pepich, Adena ; Johnsen, John Inge</creatorcontrib><description>Dysregulated expression of the transcription factor MYCN is frequently detected in nervous system tumors such as childhood neuroblastoma. Here, gene amplification of is a single oncogenic driver inducing neoplastic transformation in neural crest-derived cells. This abnormal expression is one of the strongest predictors of poor prognosis. It is present at diagnosis and is never acquired during later tumorigenesis of non-amplified neuroblastoma. This suggests that increased expression is an early event in these cancers leading to a peculiar dysregulation of cells that results in embryonal or cancer stem-like qualities, such as increased self-renewal, apoptotic resistance, and metabolic flexibility.</description><identifier>ISSN: 2234-943X</identifier><identifier>EISSN: 2234-943X</identifier><identifier>DOI: 10.3389/fonc.2020.624079</identifier><identifier>PMID: 33585251</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>cancer stem cell ; childhood cancer ; MYCN ; neural crest ; neuroblastoma ; Oncology</subject><ispartof>Frontiers in oncology, 2021-01, Vol.10, p.624079-624079</ispartof><rights>Copyright © 2021 Otte, Dyberg, Pepich and Johnsen.</rights><rights>Copyright © 2021 Otte, Dyberg, Pepich and Johnsen 2021 Otte, Dyberg, Pepich and Johnsen</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c566t-4b35dd7b6d248267fc77b9d6e42fa7e2b273f172f0c93bf188025c4900f0ede73</citedby><cites>FETCH-LOGICAL-c566t-4b35dd7b6d248267fc77b9d6e42fa7e2b273f172f0c93bf188025c4900f0ede73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873735/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873735/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27922,27923,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33585251$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:145874337$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Otte, Jörg</creatorcontrib><creatorcontrib>Dyberg, Cecilia</creatorcontrib><creatorcontrib>Pepich, Adena</creatorcontrib><creatorcontrib>Johnsen, John Inge</creatorcontrib><title>MYCN Function in Neuroblastoma Development</title><title>Frontiers in oncology</title><addtitle>Front Oncol</addtitle><description>Dysregulated expression of the transcription factor MYCN is frequently detected in nervous system tumors such as childhood neuroblastoma. Here, gene amplification of is a single oncogenic driver inducing neoplastic transformation in neural crest-derived cells. This abnormal expression is one of the strongest predictors of poor prognosis. It is present at diagnosis and is never acquired during later tumorigenesis of non-amplified neuroblastoma. This suggests that increased expression is an early event in these cancers leading to a peculiar dysregulation of cells that results in embryonal or cancer stem-like qualities, such as increased self-renewal, apoptotic resistance, and metabolic flexibility.</description><subject>cancer stem cell</subject><subject>childhood cancer</subject><subject>MYCN</subject><subject>neural crest</subject><subject>neuroblastoma</subject><subject>Oncology</subject><issn>2234-943X</issn><issn>2234-943X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkc1v1DAQxS0EolXbOye0R4SUZeLP-IKEFgqV2nJpJThZjj0uKUm82EkR_z1eslRdXzx68-bnj0fIqxrWjDX6XYijW1OgsJaUg9LPyDGljFeas2_Pn9RH5CzneyhLCqiBvSRHjIlGUFEfk7dX3zfXq_N5dFMXx1U3rq5xTrHtbZ7iYFcf8QH7uB1wnE7Ji2D7jGf7_YTcnn-62XypLr9-vth8uKyckHKqeMuE96qVnvKGShWcUq32EjkNViFtqWKhVjSA06wNddMAFY5rgADoUbETcrFwfbT3Zpu6waY_JtrO_BNiujM2TZ3r0VhrPWjPbQPAKQsNr53EItYCtWBQWNXCyr9xO7cHtL30s1RouOSs3vnfL_7SGdC78uxk-4Oxw87Y_TB38cGoRjHFRAG82QNS_DVjnszQZYd9b0eMczblT7TQWjJarLBYXYo5JwyPx9RgdgmbXcJml7BZEi4jr59e73Hgf57sL-epoiw</recordid><startdate>20210127</startdate><enddate>20210127</enddate><creator>Otte, Jörg</creator><creator>Dyberg, Cecilia</creator><creator>Pepich, Adena</creator><creator>Johnsen, John Inge</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>ZZAVC</scope><scope>DOA</scope></search><sort><creationdate>20210127</creationdate><title>MYCN Function in Neuroblastoma Development</title><author>Otte, Jörg ; Dyberg, Cecilia ; Pepich, Adena ; Johnsen, John Inge</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c566t-4b35dd7b6d248267fc77b9d6e42fa7e2b273f172f0c93bf188025c4900f0ede73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>cancer stem cell</topic><topic>childhood cancer</topic><topic>MYCN</topic><topic>neural crest</topic><topic>neuroblastoma</topic><topic>Oncology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Otte, Jörg</creatorcontrib><creatorcontrib>Dyberg, Cecilia</creatorcontrib><creatorcontrib>Pepich, Adena</creatorcontrib><creatorcontrib>Johnsen, John Inge</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Otte, Jörg</au><au>Dyberg, Cecilia</au><au>Pepich, Adena</au><au>Johnsen, John Inge</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MYCN Function in Neuroblastoma Development</atitle><jtitle>Frontiers in oncology</jtitle><addtitle>Front Oncol</addtitle><date>2021-01-27</date><risdate>2021</risdate><volume>10</volume><spage>624079</spage><epage>624079</epage><pages>624079-624079</pages><issn>2234-943X</issn><eissn>2234-943X</eissn><abstract>Dysregulated expression of the transcription factor MYCN is frequently detected in nervous system tumors such as childhood neuroblastoma. Here, gene amplification of is a single oncogenic driver inducing neoplastic transformation in neural crest-derived cells. This abnormal expression is one of the strongest predictors of poor prognosis. It is present at diagnosis and is never acquired during later tumorigenesis of non-amplified neuroblastoma. This suggests that increased expression is an early event in these cancers leading to a peculiar dysregulation of cells that results in embryonal or cancer stem-like qualities, such as increased self-renewal, apoptotic resistance, and metabolic flexibility.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>33585251</pmid><doi>10.3389/fonc.2020.624079</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2234-943X
ispartof Frontiers in oncology, 2021-01, Vol.10, p.624079-624079
issn 2234-943X
2234-943X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_aaad09d4a800423f841c6eaad15e9530
source PubMed Central (Open Access)
subjects cancer stem cell
childhood cancer
MYCN
neural crest
neuroblastoma
Oncology
title MYCN Function in Neuroblastoma Development
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T12%3A12%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MYCN%20Function%20in%20Neuroblastoma%20Development&rft.jtitle=Frontiers%20in%20oncology&rft.au=Otte,%20J%C3%B6rg&rft.date=2021-01-27&rft.volume=10&rft.spage=624079&rft.epage=624079&rft.pages=624079-624079&rft.issn=2234-943X&rft.eissn=2234-943X&rft_id=info:doi/10.3389/fonc.2020.624079&rft_dat=%3Cproquest_doaj_%3E2489599632%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c566t-4b35dd7b6d248267fc77b9d6e42fa7e2b273f172f0c93bf188025c4900f0ede73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2489599632&rft_id=info:pmid/33585251&rfr_iscdi=true